FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Revive Therapeutics

  • Home
  •  | 
  • Tag Archives: "Revive Therapeutics"

Revive Announces Closing of the First Tranche of Its Non-Brokered Private Placement for Total Gross Proceeds of Over $1 Million

Revive Announces Closing of the First Tranche of Its Non-Brokered Private Placement for Total Gross Proceeds of Over $1 Million
Feb. 05, 2019 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV) (OTCQB: RVVTF) is pleased to announce that it has completed the first tranche of the non-brokered private placement previously announced in the December 7, 2018 and January 23, 2019 news releases for a total of 10,960,000 units (“Units”), at a price of $0.10 per Unit for gross proceeds of $1,096,000. (the “Offering”).
Read more

Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation
Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) ("Revive" or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for cannabidiol (“CBD”) in the prevention of ischemia and reperfusion injury (“IRI”) resulting from solid organ transplantation.
Read more

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2018

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2018
Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced its results for the fiscal year ended June 30, 2018.  The Audited Financial Statements and Management's Discussion and Analysis for the year ended June 30, 2018, may be viewed on SEDAR at www.sedar.com.
Read more

Revive Therapeutics Introduces RELICANN™ a New Brand for Hemp-based CBD Wellness and Medical Cannabis Market

Revive Therapeutics Introduces RELICANN™ a New Brand for Hemp-based CBD Wellness and Medical Cannabis Market
Sept. 11, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced the introduction of RELICANN™, the Company’s hemp-based  and medical cannabis brand designed for the health and wellness and medical cannabis consumer.  The Company’s first product under the RELICANN™ brand is RELICANN™ hemp-based Cannabidiol (“CBD”) gum, which will be available in Canada in the fourth-quarter of 2018.
Read more